Boehringer acquires Korean approval of IPF treatment ‘Ofev’

Published: 2016-10-31 13:59:01

Updated: 2016-10-31 13:59:01

Boehringer Ingelheim Korea(CEO Ki-Hwan Park) announced acquisition of product approval for its idiopathic pulmonary fibrosis(IPF) treatment, Ofev Soft Cap(generic name: nintedanib esylate), from the Korean Ministry of Food and Drug Safety(MFDS) on the 21^st.

Ofev Soft Cap has two volume types, 150mg and 100mg, and needs to be administered twice a day, a capsule for each time and every 12 hours...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.